spacer
home > ebr > winter 2019 > gates and doors
PUBLICATIONS
European Biopharmaceutical Review

Gates and Doors

Important discoveries have enabled continued progress in biopharmaceutical sciences; the Nobel Prize in Chemistry was awarded jointly to Frances Arnold for the directed evolution of enzymes and to George Smith and Sir Gregory Winter for the phage display of peptides and antibodies. This work will accelerate the pace of biopharmaceutical drug discovery and open up opportunities for new agents. The Nobel Prize in physiology or medicine was awarded to James Allison and Tasuku Honjo for the discovery of cancer therapy by the inhibition of negative immune regulation. The result of their research, immune checkpoint therapy, is recognised as the fourth pillar in the fight against cancer, supplementing surgery, radiation, and chemotherapy. It has fundamentally changed the outcome for certain groups of patients with advanced cancers.

At the same time, much work remains to be done in the quest to mitigate chronic diseases. The war on cancer persists as steady progress is made in precision medicine. The majority of recent drug approvals have received breakthrough therapy designation by the FDA. These focus mainly on targeted therapies, reflecting greater understanding of the underlying mechanisms. Among the major tumour types, biomarkers help specify patient treatment protocols and to distinguish different cancers, beyond more than just tissue types.

Cancer immunotherapy studies number in the thousands. The enthusiasm for this approach relates to the stunning success achieved in just a few years – alone or in combination protocols. After initial tissue-specific experience, the field has quickly evolved toward a tissue-agnostic paradigm, based on genetic biomarkers.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Protagen Protein Services (PPS) reaches new level in characterizing HCP protein impurities

In response to current regulatory guidance a Mass Spectrometry (MS) based Host Cell Protein (HCP) detection approach with faster, more accurate and wider-ranging detection is essential. In order to meet the newly prevailing demands Protagen Protein Services (PPS) recently invested in more far-reaching MS capabilities: The new high-performing mass spectrometer ThermoFisher Q Exactive™ HF-X started operational service last month and brings PPS to the next level of reproducible, accurate and sensitive analyses of majorly complex samples for different aspects of translational research and biopharma applications.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

ASGCT 22nd Annual Meeting

29 April - 2 May 2019, Washington Hilton, Washington, D.C

The 2019 ASGCT Annual Meeting is expected to be the largest in Society history, eclipsing the mark set by the 2018 meeting just last year. Join more than 3,500 researchers, clinicians, advocates, and industry leaders in discovering the latest science and technology surrounding gene and cell therapy.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement